Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN N UNGAR

Allopathic & Osteopathic Physicians Dermatology

NPI
1912435462
CMS profile
8807563
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$5,995.77

82 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN N UNGAR

NPI 1912435462 · CMS profile ID 8807563

Allopathic & Osteopathic Physicians / Dermatology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912435462?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN N UNGAR, NPI 1912435462, CMS profile ID 8807563. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912435462?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BENJAMIN N UNGAR, NPI 1912435462, CMS profile ID 8807563. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912435462?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BENJAMIN N UNGAR, NPI 1912435462, CMS profile ID 8807563, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1912435462?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

82 matching records · $5,995.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 82 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–82 of 82.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $13.7405/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283421 CMS
ABBVIE INC. $52.8005/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892567009 CMS
Janssen Biotech, Inc. $24.7904/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283409 CMS
Janssen Biotech, Inc. $34.8904/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283415 CMS
Lilly USA, LLC $23.0904/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917901583 CMS
Janssen Biotech, Inc. $2.7504/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283479 CMS
Janssen Biotech, Inc. $4.3504/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283485 CMS
Janssen Biotech, Inc. $3.0704/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283473 CMS
LEO Pharma Inc. $191.3804/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936298849 CMS
GENZYME CORPORATION $24.7004/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939107191 CMS
ABBVIE INC. $12.4103/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892567007 CMS
Janssen Biotech, Inc. $118.0003/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283384 CMS
Regeneron Healthcare Solutions, Inc. $6.1603/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927454307 CMS
ABBVIE INC. $78.1603/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892567005 CMS
E.R. Squibb & Sons, L.L.C. $9.9503/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061072297 CMS
E.R. Squibb & Sons, L.L.C. $87.5203/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932858457 CMS
Janssen Biotech, Inc. $12.6303/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283399 CMS
Sun Pharmaceutical Industries Inc. $17.4403/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947731115 CMS
PFIZER INC. $24.3103/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949621723 CMS
Regeneron Healthcare Solutions, Inc. $28.4803/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927454301 CMS
Janssen Biotech, Inc. $3.8803/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283427 CMS
Janssen Biotech, Inc. $26.3003/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283433 CMS
LEO Pharma Inc. $21.6202/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936298843 CMS
Incyte Corporation $17.6602/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943069507 CMS
Janssen Biotech, Inc. $32.4902/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283455 CMS
ABBVIE INC. $15.7502/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892567003 CMS
GENZYME CORPORATION $24.3502/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939107171 CMS
ABBVIE INC. $100.5802/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892567001 CMS
Regeneron Healthcare Solutions, Inc. $30.0501/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927454295 CMS
ABBVIE INC. $8.4401/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892566997 CMS
ABBVIE INC. $27.4801/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892566999 CMS
Janssen Biotech, Inc. $23.9601/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886283403 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $696.21 24
PY2022 $5,995.77 82
PY2023 $18,770.02 127
PY2024 $44,934.85 243
PY2025 $86,787.72 234

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $940.00 1
PY2025 Principal investigator $744,063.30 27
PY2024 Principal investigator $550,098.50 9
PY2023 Principal investigator $122,667.00 2
PY2022 Principal investigator $157,497.38 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $27,021.00 12/22/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140878
Principal investigator 1 SANOFI US SERVICES INC. $19,756.30 12/08/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140870
Principal investigator 1 Incyte Corporation $134,380.00 11/18/2025 Non-covered Recipient Entity
Icahn School of Medicine at Mt. Sinai
Characterizing the Molecular Cutaneous Phenotype of Seborrheic Dermatitis and Treatment Response to Ruxolitinib 1.5 percent Cream No dispute reported 06/30/2026 1240538872
Principal investigator 1 SANOFI US SERVICES INC. $26,840.00 11/10/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140857
Principal investigator 1 SANOFI US SERVICES INC. $31,031.00 11/10/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140865
Principal investigator 1 SANOFI US SERVICES INC. $14,127.00 10/06/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140848
Principal investigator 1 SANOFI US SERVICES INC. $12,811.00 09/15/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140841
Principal investigator 1 SANOFI US SERVICES INC. $21,269.40 09/03/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140838
Principal investigator 1 SANOFI US SERVICES INC. $26,403.50 08/18/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140806
Principal investigator 1 SANOFI US SERVICES INC. $16,630.00 08/18/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140810
Principal investigator 1 SANOFI US SERVICES INC. $20,893.00 07/14/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140776
Principal investigator 1 SANOFI US SERVICES INC. $29,621.50 07/07/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140779
Principal investigator 1 SANOFI US SERVICES INC. $25,539.00 06/16/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140764
Principal investigator 1 SANOFI US SERVICES INC. $26,325.50 06/09/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140757
Recipient PFIZER INC. $940.00 05/30/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760536
Principal investigator 1 SANOFI US SERVICES INC. $12,034.00 05/19/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140768
Principal investigator 1 SANOFI US SERVICES INC. $750.00 05/19/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140772
Principal investigator 1 SANOFI US SERVICES INC. $27,439.00 05/12/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140750
Principal investigator 1 SANOFI US SERVICES INC. $19,669.80 05/05/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140739
Principal investigator 1 SANOFI US SERVICES INC. $4,668.00 04/21/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140735
Principal investigator 1 SANOFI US SERVICES INC. $26,245.00 04/14/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140729
Principal investigator 1 SANOFI US SERVICES INC. $25,064.60 04/07/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140686
Principal investigator 1 SANOFI US SERVICES INC. $64,128.00 03/24/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140696
Principal investigator 1 SANOFI US SERVICES INC. $17,290.00 03/10/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140885
Principal investigator 1 SANOFI US SERVICES INC. $12,727.20 03/04/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140699
Principal investigator 1 SANOFI US SERVICES INC. $28,690.00 02/18/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140890
Principal investigator 1 SANOFI US SERVICES INC. $17,679.50 02/04/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140881
Principal investigator 1 SANOFI US SERVICES INC. $55,030.00 01/24/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226140887